<DOC>
	<DOCNO>NCT02496078</DOCNO>
	<brief_summary>The purpose study determine whether regimen consist daclatasvir asunaprevir effective treatment-naive patient chronic hepatitis genotype 1b infection .</brief_summary>
	<brief_title>A Phase 3 Evaluation Daclatasvir Asunaprevir Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients chronically infected HCV Genotype 1b No previous exposure interferon formulation , Ribavirin ( RBV ) , HCV direct act antiviral agent HCV RNA viral load ≥ 10,000 IU/mL screen Seronegative HIV HBsAg BMI 1835 kg/m2 , inclusive Patients compensate cirrhosis permit Infection HCV genotype ( GT ) 1b Evidence decompensated liver disease include , limited , history presence ascites , bleed varix , hepatic encephalopathy Evidence medical condition contribute chronic liver disease HCV Diagnosed suspect hepatocellular carcinoma malignancy Uncontrolled diabetes hypertension History moderate severe depression . Wellcontrolled mild depression allow Confirmed alanine aminotransferase ( ALT ) ≥ 5x Upper Limit Normal ( ULN ) Confirmed platelet count &lt; 50,000 cells/mm3 Confirmed hemoglobin &lt; 8.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>